View Item 

Show simple item record

International workshop on immune tolerance induction: consensus recommendations 1

dc.contributor.authorDimichele, D. M.en_US
dc.contributor.authorHoots, W. K.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorRivard, G. E.en_US
dc.contributor.authorSantagostino, E.en_US
dc.date.accessioned2010-06-01T20:15:43Z
dc.date.available2010-06-01T20:15:43Z
dc.date.issued2007-07en_US
dc.identifier.citationDIMICHELE, D. M.; HOOTS, W. K.; PIPE, S. W.; RIVARD, G. E.; SANTAGOSTINO, E. (2007). "International workshop on immune tolerance induction: consensus recommendations 1 ." Haemophilia 13(s1): 1-22. <http://hdl.handle.net/2027.42/73382>en_US
dc.identifier.issn1351-8216en_US
dc.identifier.issn1365-2516en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73382
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17593277&dopt=citationen_US
dc.format.extent933396 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compliation 2007 Blackwell Publishing Ltden_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherFactor IXen_US
dc.subject.otherHemophilia Aen_US
dc.subject.otherHemophilia Ben_US
dc.subject.otherImmune Tolerance Inductionen_US
dc.subject.otherInhibitorsen_US
dc.titleInternational workshop on immune tolerance induction: consensus recommendations 1en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Department of Pediatrics, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* Department of Pediatrics, Weill Medical College of Cornell University, New York, NYen_US
dc.contributor.affiliationother† Department of Pediatrics, University of Texas Medical School, Houston, TXen_US
dc.contributor.affiliationother§ Department of Pediatrics, University of Montreal, QC, Canada;en_US
dc.contributor.affiliationother¶ A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, Milan, Italyen_US
dc.identifier.pmid17593277en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73382/1/j.1365-2516.2007.01497.x.pdf
dc.identifier.doi10.1111/j.1365-2516.2007.01497.xen_US
dc.identifier.sourceHaemophiliaen_US
dc.identifier.citedreferenceWhite GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in haemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.en_US
dc.identifier.citedreferenceBrackmann HH, Wallny T. Immune tolerance: high-dose regimen. In: Rodriguez-Merchan E.C., ed. Inhibitors in Patients with haemophilia. Oxford, England: Blackwell Science, Ltd, 2002: pp. 45 – 48.en_US
dc.identifier.citedreferenceKessler CM. New perspectives in hemophilia treatment. Hematol Am Soc Hematol Educ Program 2005: 429 – 35.en_US
dc.identifier.citedreferenceUK Haemophilia Centre Doctors’ Organisation (UKHCDO). The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 1047 – 54.en_US
dc.identifier.citedreferenceHay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 2000; 111: 78 – 90.en_US
dc.identifier.citedreferenceLeissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187 – 93.en_US
dc.identifier.citedreferenceHilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626 – 30.en_US
dc.identifier.citedreferenceNegrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113 – 9.en_US
dc.identifier.citedreferenceKey NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912 – 8.en_US
dc.identifier.citedreferenceShapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773 – 8.en_US
dc.identifier.citedreferenceArkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency – use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255 – 9.en_US
dc.identifier.citedreferenceTjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 2004; 10 ( Suppl. 2 ): 41 – 5.en_US
dc.identifier.citedreferenceAstermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor. Blood 2007; 109: 546 – 51.en_US
dc.identifier.citedreferenceHo AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547 – 54.en_US
dc.identifier.citedreferenceDiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10 ( Suppl. 4 ): 140 – 5.en_US
dc.identifier.citedreferenceLeissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 ( Suppl. 3 ): 25 – 32.en_US
dc.identifier.citedreferenceBrackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.en_US
dc.identifier.citedreferenceHay CRM. Inhibitors to factor VIII/IX: treatment of inhibitors – immune tolerance induction. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Malden, MA: Blackwell Publishing Ltd: 2005; 74 – 9.en_US
dc.identifier.citedreferenceDiMichele D. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12: 81 – 6.en_US
dc.identifier.citedreferenceMariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 ( Suppl. 1 ): 25 – 7.en_US
dc.identifier.citedreferenceLenk H. The German Registry of immune tolerance treatment in hemophilia – 1999 update. Haematologica 2000; 85: 45 – 7.en_US
dc.identifier.citedreferenceDiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52 – 7.en_US
dc.identifier.citedreferenceDiMichele DM, Hay CR. The international immune tolerance study: a multicenter prospective randomized trial in progress. J Thromb Haemost 2006; 4: 2271 – 3.en_US
dc.identifier.citedreference 24 Agency for Health Care Policy and Research. Guidelines on the Use of Colony-stimulating Factors in Haematological Malignancies. Rockville, MD: US Department of Health and Human Services. Agency for Health Care Policy and Research; 1993. AHCPR publication 92-0023.en_US
dc.identifier.citedreferenceBray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428 – 35.en_US
dc.identifier.citedreferenceDiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280 – 7.en_US
dc.identifier.citedreferenceSchwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402 – 6.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739 – 45.en_US
dc.identifier.citedreferenceAstermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167 – 72.en_US
dc.identifier.citedreferenceAstermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263 – 5.en_US
dc.identifier.citedreferenceAstermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267 – 72.en_US
dc.identifier.citedreferenceLusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574 – 83.en_US
dc.identifier.citedreferenceLee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost 2006; 32 ( Suppl. 2 ): 10 – 4.en_US
dc.identifier.citedreferenceLorenzo J, Lopez A, Altisent C, Aznar J. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600 – 3.en_US
dc.identifier.citedreferenceKoestenberger M, Raith W, Muntean W. High titre inhibitor after continuous factor VIII administration for surgery in a young infant. Haemophilia 2000; 6: 120.en_US
dc.identifier.citedreferenceAstermark J. Overview of inhibitors. Semin Hematol 2006; 43: S3 – S7.en_US
dc.identifier.citedreferenceGoudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46 – 51.en_US
dc.identifier.citedreferenceKroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77 ( Suppl. 1 ): 33 – 7.en_US
dc.identifier.citedreferenceHaya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154 – 9.en_US
dc.identifier.citedreferenceFreiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982–1995. Haemophilia 1999; 5: 32 – 9.en_US
dc.identifier.citedreferenceOldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ’Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 ( Suppl. 1 ): 49 – 54.en_US
dc.identifier.citedreferenceSmith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35 – 8.en_US
dc.identifier.citedreferenceDamiano ML, Hutter JJ. Jr Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000; 6: 526 – 32.en_US
dc.identifier.citedreferenceRocino A, Papa M, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33 – 8.en_US
dc.identifier.citedreferenceMauser-Bunschoten EP, Roosendaal G, van den Berg HM. Low-dose immune tolerance therapy: the van creveld model. Vox Sang 1996; 70 ( Suppl. 1 ): 66 – 7.en_US
dc.identifier.citedreferenceNilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947 – 50.en_US
dc.identifier.citedreferenceBerntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70 ( Suppl. 1 ): 36 – 41.en_US
dc.identifier.citedreferenceChabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird, LE, Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th edn. New York, NY: McGraw-Hill Medical Publishing Division, 2001: 1395.en_US
dc.identifier.citedreferenceGruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82 – 7.en_US
dc.identifier.citedreferenceMauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994; 71: 703 – 6.en_US
dc.identifier.citedreferenceBrackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors – twenty years’‘Bonn protocol’. Vox Sang 1996; 70 ( Suppl. 1 ): 30 – 5.en_US
dc.identifier.citedreferenceMariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155 – 8.en_US
dc.identifier.citedreferenceDiMichele D, Kroner B. and The ISTH Factor VIII/IX Subcommitee. Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: current practice implications. Vox Sang 1999; 77: 31 – 2.en_US
dc.identifier.citedreferenceDiMichele DM, Kroner BL, North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52 – 7.en_US
dc.identifier.citedreferenceMariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003; 29: 69 – 76.en_US
dc.identifier.citedreferenceMauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983 – 8.en_US
dc.identifier.citedreferenceAstermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363 – 71.en_US
dc.identifier.citedreferenceHay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591 – 605.en_US
dc.identifier.citedreferenceRocino A, Salerno E, Capasso F et al. Secondary prophylaxis in severe haemophilia A: results in preventing further joint damage [abstract]. Thromb Haemost 1999; 82: 610. Abstract 1923A.en_US
dc.identifier.citedreferenceUnuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000; 6: 150 – 7.en_US
dc.identifier.citedreferenceBarnes C, Rivard GE, Poon MC et al. Canadian multi-institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT. Haemophilia 2006; 12: 1 – 6.en_US
dc.identifier.citedreferenceRocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558 – 61.en_US
dc.identifier.citedreferenceKreuz W. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.en_US
dc.identifier.citedreferenceKreuz W, Escuriola-Ettingshausen C, Auerswald G. Immune tolerance induction in haemophilia A patients with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86 ( Suppl. 4 ): 16 – 20.en_US
dc.identifier.citedreferenceAuerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.en_US
dc.identifier.citedreferenceOrsini F, Rothschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288 – 90.en_US
dc.identifier.citedreferenceGringeri A, Musso R, Bernasconi S. Immunotolerance induction (ITI) with high purity FVIII/VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005; 3 ( Suppl. 1 ): A207.en_US
dc.identifier.citedreferenceMannucci PM, Chediak J, Hanna W et al. and The Alphanate Study Group Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450 – 6.en_US
dc.identifier.citedreferenceFederici AB. The factor VIII/von Willebrand factor complex: basic and clinicalk issues. Haematologica 2003; 88 ( Suppl. 9 ): EREP02.en_US
dc.identifier.citedreferenceBehrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221 – 9.en_US
dc.identifier.citedreferenceKasper C. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Treatment of Hemophilia: World Federation of Hemophilia, 2004.en_US
dc.identifier.citedreferenceBerntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001; 7: 109 – 13.en_US
dc.identifier.citedreferenceEttingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16 ( Suppl. 1 ): S27 – 31.en_US
dc.identifier.citedreferenceSuzuki T, Arai M, Amano K, Kagawa K and Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749 – 54.en_US
dc.identifier.citedreferenceGensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369 – 74.en_US
dc.identifier.citedreferenceKallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375 – 80.en_US
dc.identifier.citedreferenceBerntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance ? Haematologica 2003; 88: EREP03.en_US
dc.identifier.citedreferenceFreedman J, Rand ML, Russell O et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: 1508 – 13.en_US
dc.identifier.citedreferenceKnobl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999; 77 ( Suppl. 1 ): 57 – 64.en_US
dc.identifier.citedreferenceRivard GE, St Louis J, Lacroix S, Champagne M and Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711 – 6.en_US
dc.identifier.citedreferenceManco-Johnson MJ, Abshire T, Brown D et al. Initial results of a randomized prospective trial of prophylaxis to prevent joint disease in young children with factor VIII(FVIII) deficiency [abstract]. Blood 2005; 106: Abstract 3.en_US
dc.identifier.citedreferenceShapiro AD, Donfield SM, Lynn HS et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001; 108: E105.en_US
dc.identifier.citedreferencePanicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272 – 8.en_US
dc.identifier.citedreferenceLusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179 – 88.en_US
dc.identifier.citedreferenceKreuz W, Escuriola-Ettingshausen C, Mentzer D et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 266a. Abstract 1141.en_US
dc.identifier.citedreferenceValentino L. FEIBA prophylaxis in hemophilia A patients with inhibitors results in a 95% reduction in bleeding episodes. Bangkok, Thailand: Abstract presented at: 26th World Federation of Hematology Congress; October 17–21, 2004, 2004.en_US
dc.identifier.citedreferenceLindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638 – 48.en_US
dc.identifier.citedreferenceVillar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352 – 9.en_US
dc.identifier.citedreferenceVaradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374 – 80.en_US
dc.identifier.citedreferenceKonkle BA, Ebbesen LS, Friedrich U et al. Secondary Prophylactic Treatment with rFVIIa in Patients with Haemophilia A or B and Inhibitors with High Requirements for On-demand Treatment: Analysis of Primary Endpoint and Safety. Vancouver, Canada: Poster presented at: XXVII International Congress of the World Federation of Hemophilia; 21–5 May 2006.en_US
dc.identifier.citedreferenceSaxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126 – 7.en_US
dc.identifier.citedreferenceEhrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83 – 90.en_US
dc.identifier.citedreferenceKreuz W, Escuriola-Ettingshausen C, Martinez I, Mentzer D, Figura S, Klarmann D. Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 265a. Abstract 1140.en_US
dc.identifier.citedreferenceHilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261 – 8.en_US
dc.identifier.citedreferenceAntunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003; 9: 573 – 7.en_US
dc.identifier.citedreferenceCarcao MD, Connolly BL, Chait P et al. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 9: 578 – 83.en_US
dc.identifier.citedreferenceEwenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004; 10: 629 – 48.en_US
dc.identifier.citedreferenceValentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134 – 46.en_US
dc.identifier.citedreferenceTarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003; 9: 588 – 92.en_US
dc.identifier.citedreferenceWarrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment center experience. Haemophilia 1997; 3: 194 – 8.en_US
dc.identifier.citedreferenceBollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000; 6: 66 – 70.en_US
dc.identifier.citedreferenceDomm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003; 9: 50 – 6.en_US
dc.identifier.citedreferencevan Dijk K, van Der Bom JG, Bax KN, Van Der Zee DC and Van Den Berg MH. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004; 89: 189 – 94.en_US
dc.identifier.citedreferencevan den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia – a review. Haemophilia 1998; 4: 418 – 20.en_US
dc.identifier.citedreferenceHay CRM, Keegan J, Goldstone J et al. International Immune Tolerance (ITI) Study: Frequency of Central Venous Line Infection and Effect on ITI Outcome. Poster presented at: 27th World Federation of Hematology Congress; 21–25 May 2006; Vancouver, Canada. 2006.en_US
dc.identifier.citedreferenceJourneycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727 – 31.en_US
dc.identifier.citedreferenceSantagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol 2003; 123: 502 – 6.en_US
dc.identifier.citedreference108 National Institute of Diabetes and Digestive and Kidney Diseases. Vascular Access for Hemodialysis. NIH Publication no. 05-4554. January 2005. Available at: http://www.kidney.niddk.nih.gov/kudiseases/pubs/pdf/vascularaccess.pdf. (accessed on 17 January 2007).en_US
dc.identifier.citedreferenceCarcao M, St Louis J, Poon MC et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7 – 18.en_US
dc.identifier.citedreferenceCollins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12 ( Suppl. 6 ): 94 – 101.en_US
dc.identifier.citedreferenceWiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426 – 8.en_US
dc.identifier.citedreferenceStasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424 – 8.en_US
dc.identifier.citedreferenceDunkley S, Lindeman R. Successful treatment of a high titre factor VIII inhibitor with rituximab alone [abstract]. J Thromb Haemost 2005; 3 ( Suppl. 1 ): Abstract P631.en_US
dc.identifier.citedreferenceEscobar M, Kempton C and Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab [abstract]. Blood 2002; 100: 109b abstract 3915.en_US
dc.identifier.citedreferenceCurry N, Stanworth S, Keeling D. The use of rituximab in two children with allo-antibodies towards factor VIII. Br J Haematol 2006; 133: 214 – 6.en_US
dc.identifier.citedreferenceCurtin J, Misra A, Teo J, Webster B, Lammi A. Use of rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia A [abstract]. Haemophilia 2004; 10 ( Suppl. 3 ): 57. Abstract 30.en_US
dc.identifier.citedreferenceLinde R, Escuriola-Ettinghausen C, Konigs C, Dunsch D, Stoll H. Kreuz W. Rituximab as a new inhibitor elimination agent in high-titer inhibitor patients – a long-term follow-up [abstract]. Haemophilia 2004; 10 ( Suppl. 3 ): 60. Abstract 51.en_US
dc.identifier.citedreferenceMateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thromb Haemost 2006; 95: 386 – 7.en_US
dc.identifier.citedreferenceMathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366 – 8.en_US
dc.identifier.citedreferenceMedeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy [abstract]. Blood 2002; 100: 103b. Abstract 3890.en_US
dc.identifier.citedreferenceMoschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K. Tzortzatou-Stathopoulou F. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95 – 9.en_US
dc.identifier.citedreferencePruthi RK, Schmidt KA, Slaby JA, Hook CC, Nichols WL. Rituximab treatment of FVIII inhibitors in congenital hemophilia A (cHA) [abstract]. J Thromb Haemost 2005; 3 ( Suppl. 1 ): Abstract P652.en_US
dc.identifier.citedreferenceFox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218 – 22.en_US
dc.identifier.citedreference124 IITI. International, Randomised, Controlled Trial of Immune-tolerance Induction. Available at: http://www.itistudy.com (accessed on 12 January 2007).en_US
dc.identifier.citedreferenceTeitel J. Inhibitor economics. Semin Hematol 2006; 43: S14 – S17.en_US
dc.identifier.citedreferenceMariani G, Kroner B. Immune tolerance in hemophilia and inhibitors: a cost analysis. Transfusion 2000; 40: 495 – 6.en_US
dc.identifier.citedreferenceColowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698 – 702.en_US
dc.identifier.citedreferenceGringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358 – 63.en_US
dc.identifier.citedreferenceGringeri A, Mantovani L, Mackensen SV. Quality of life assessment in clinical practice in haemophilia treatment. Haemophilia 2006; 12 ( Suppl. 3 ): 22 – 9.en_US
dc.identifier.citedreferenceWasserman J, Aday LA, Begley CE, Ahn C, Lairson DR. Measuring health state preferences for hemophilia: development of a disease-specific utility instrument. Haemophilia 2005; 11: 49 – 57.en_US
dc.identifier.citedreferenceScalone L, Mantovani LG, Mannucci PM, Gringeri A. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154 – 62.en_US
dc.identifier.citedreferenceKreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24 – 32.en_US
dc.identifier.citedreferenceHay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558 – 63.en_US
dc.identifier.citedreferenceHay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762 – 6.en_US
dc.identifier.citedreferenced'Oiron R, Volot F, Reynaud J et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia A and inhibitors. Semin Hematol 2006; 43: S3 – S9.en_US
dc.identifier.citedreferenceDiMichele DM. Management of factor VIII inhibitors. Int J Hematol 2006; 83: 119 – 25.en_US
dc.identifier.citedreferenceKey NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379 – 91.en_US
dc.identifier.citedreferenceWarrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis 1998; 9 ( Suppl. 1 ): S125 – 8.en_US
dc.identifier.citedreferenceWarrier I, Ewenstein BM, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23 – 7.en_US
dc.identifier.citedreferenceThorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5: 101 – 5.en_US
dc.identifier.citedreferenceKetterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54: 201 – 13.en_US
dc.identifier.citedreferenceEwenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115 – 6.en_US
dc.identifier.citedreferenceDiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12 ( Suppl. 6 ): 81 – 86.en_US
dc.identifier.citedreferenceWermes C, von Depka Prondzinski M, Welte K, Sykora K.-W. New strategy for the treatment of factor IX inhibitors in severe haemophilia B [abstract]. Blood 2000; 96: 267A. Abstract 1148.en_US
dc.identifier.citedreferenceAnanyeva NM, Lacroix-Desmazes S, Hauser CA et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis 2004; 15: 109 – 24.en_US
dc.identifier.citedreferenceReding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12 ( Suppl. 6 ): 30 – 6.en_US
dc.identifier.citedreferenceTarantino M, Ma A, Aledort L. Safety of human plasma-derived clotting factor products and their role in hemostasis in patients with hemophilia: meeting report. Haemophilia ( in press ).en_US
dc.identifier.citedreferenceDasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610 – 2.en_US
dc.identifier.citedreferenceBarnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report. Haemophilia 2001; 7: 439 – 40.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2516.2007.01497.x.pdf
Size:
911.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.